Business Daily Media

Business Marketing


Meet the CEO who is taking the global stage to reform clinical trials

Clinical trials are the lifeline of the healthcare industry, propelling the development of innovative treatments and therapies for a wide spectrum of medical conditions. Surprisingly, many individuals remain unaware of the significance and breadth of clinical trials, often mistakenly associating them exclusively with vaccines and oncology. However, the reality is that clinical trials encompass a diverse range of medical interventions, including drugs, devices, and behavioural therapies, playing a pivotal role in advancing healthcare.

Charlotte Bradshaw, the CEO of Evrima Technologies, a pioneering Australian firm specialising in clinical trial recruitment solutions, aims to change public perception. Drawing a parallel between participating in clinical trials and donating blood, she emphasises their crucial role in advancing medical knowledge and improving healthcare outcomes for individuals and communities. "Without research participants, we would not have the opportunity to bring new therapies to market. It is equally important to raise awareness of clinical trials as a care option, empowering both patients and clinicians through technology," Charlotte explains.

Since February 2021, Evrima Technologies has experienced exponential growth, expanding its products and services. The achievements of the company in a short span of time are noteworthy:

  • Team Expansion: The company has witnessed a remarkable 43.5% growth in its workforce, reflecting the increasing demand for its services.

  • Successful Partnerships: Evrima Technologies has secured contracts with leading bio-pharmaceutical clients, many of whom have become repeat customers, highlighting the value they find in the company's offerings.

  • Recognition and Awards: The company's exceptional performance has been acknowledged by prestigious organisations. It ranked #29 in the AFR Fast 100 Starters for 2022 and received the Female Leadership Award at Deloitte's Tech Fast 50 Australia 2021. Additionally, it secured the Rising Star Award, further highlighting its remarkable progress.

According to Charlotte Bradshaw, the future of clinical trials in Australia looks promising, largely due to the integration of technology. Notably, technology has played a crucial role in connecting clinical trials to individuals residing in rural and remote areas. Furthermore, the company's ability to translate clinical trial documentation into multiple languages has broken down language barriers, benefiting participants with English as a second language. This inclusivity fosters greater diversity and ensures that a wider range of individuals can contribute to medical research.

Bradshaw also points to the impact of the COVID-19 pandemic, which has demonstrated the potential of remote communication and online services. Just as online shopping and home deliveries have transformed our daily lives, the same convenience can be extended to clinical trials. Participants would no longer be required to attend in-person visits on a regular basis, enabling them to contribute to research from the comfort of their own homes. This innovative approach not only enhances convenience but also addresses the longstanding challenge of lengthy trial durations. On average, it takes a decade or more for new treatments to reach the market. By leveraging cutting-edge technology, Evrima Technologies aims to reduce the administrative burden on researchers, allowing them to focus on the critical clinical work necessary to expedite the journey from laboratory to patient care.

The integration of technology into clinical trials represents a monumental leap forward for the healthcare industry. Evrima Technologies, under the visionary leadership of Charlotte Bradshaw, has embraced this opportunity to revolutionise the recruitment process, bringing trials to the fingertips of individuals who can contribute to medical advancements. By creating awareness, breaking down barriers, and streamlining the research process, technology is paving the way for faster and more efficient development of life-changing treatments and therapies. As we look to the future, it is crucial that we continue to support and foster the growth of innovative solutions that empower both patients and researchers, ultimately transforming the landscape of healthcare for the better.

For more information about Evrima Technologies, please visit


Settle Easy shakes up Billion Dollar conveyancing industry

Online army of conveyancers disrupting traditional services with a fast, transparent and flexible approach Australia’s number one online conveyancing platform and service is available to customers nationally from today, after...

Interest rates up another 50 basis points with more hikes to come

As widely expected, the Reserve Bank of Australia (RBA) lifted interest rates by another 50 basis points today. The fourth rate hike in as many months, today’s decision takes the cash rate from an emergency low of 0.1% to 1.85%...

Tecala Acquires rapidMATION To Scale Capabilities in Automation and AI Solutions

Leading technology service provider Tecala Group today announced the acquisition of market leading intelligent automation group, rapidMATION. The investment comes off the back of a capital raise concluded in 2022 to fuel the gr...